ARROWHEAD PHARMACEUTICALS, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Daniel S. GoldmanHouse · D · NY |
ARWRARROWHEAD PHARMACEUTICALS, INC. · Stock |
Sale $1,001 - $15,000 |
Feb 24, 2023 | Jan 31, 2023 | Filing ↗ |
Whale Activity
- Increased172
- New64
- Held62
- Decreased166
- Closed72
- No prior filing23
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 15.1M | $991.0M | increased |
| Avoro Capital Advisors LLC | 11.0M | $720.0M | decreased |
| FMR LLC | 9.4M | $612.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.2M | $406.5M | decreased |
| STATE STREET CORP | 6.1M | $400.7M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $400.5M | increased |
| Vestal Point Capital, LP | 4.8M | $315.1M | increased |
| Invesco Ltd. | 3.8M | $250.4M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $234.5M | decreased |
| FRED ALGER MANAGEMENT, LLC | 3.3M | $213.1M | decreased |
| Siren, L.L.C. | 2.3M | $149.9M | increased |
| MORGAN STANLEY | 1.8M | $120.1M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| PERRY MICHAEL SDirector | Sale | −11.6K | $87.30 | $1.0M | Aug 18, 2026 | Form 4 ↗ |
| OLUKOTUN ADEOYE YDirector | Sale | −2,000 | $86.96 | $174K | Aug 18, 2026 | Form 4 ↗ |
| Cohen Matthew GregoryDirector | Grant / award | +11.9K | $0.00 | $0 | Jun 15, 2026 | Form 4 ↗ |
| Lu HongboDirector | Sale | −2,970 | $76.88 | $228K | May 12, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −10.0K | $75.00 | $750K | Apr 23, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −8,730 | $71.92 | $628K | Apr 22, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −1,157 | $70.45 | $82K | Apr 22, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Sale | −3,208 | $70.11 | $225K | Apr 22, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −10.0K | $64.19 | $642K | Mar 5, 2026 | Form 4 ↗ |
| Apel Daniel JosephChief Financial Officer | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Grant / award | +75.0K | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −440 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −440 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| O'Brien PatrickCOO | Gift | −540 | $0.00 | $0 | Jan 6, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −309 | $68.00 | $21K | Jan 5, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −437 | $65.97 | $29K | Jan 5, 2026 | Form 4 ↗ |
| Hamilton James CChief Medical Officer | Sale | −1,200 | $64.49 | $77K | Jan 5, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 4.8M | $392.9M | 0.32% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.2M | $346.1M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.1M | $250.1M | 0.13% | Jun 30, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 2.6M | $214.5M | 0.22% | Aug 31, 2026 |
| Invesco S&P MidCap Momentum ETF Invesco Exchange-Traded Fund Trust | 1.7M | $147.0M | 2.05% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $144.2M | 0.31% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $131.6M | 0.13% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.4M | $114.7M | 1.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.3M | $98.3M | 0.30% | Apr 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 1.2M | $95.0M | 3.38% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ARWR's shares (CUSIP 04280A100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 9.3M shares6.6%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 9.3M shares6.6%
Nov 5, 2026 · ↗ - Behzad AghazadehSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
Aug 14, 2026 · ↗ - Avoro Capital Advisors LLCSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
Aug 14, 2026 · ↗ - Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 6.4M shares4.5%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 14.2M shares10.1%
Jul 27, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
May 6, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming ARROWHEAD PHARMACEUTICALS, INC. as the client.
Government Contracts
No federal contract awards found for ARROWHEAD PHARMACEUTICALS, INC..
U.S. Patents
No USPTO patent applications found for ARROWHEAD PHARMACEUTICALS, INC..
Annual Financials
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $450.8M | $829.4M | $3.6M | $240.7M | $243.2M |
| Operating income | -$707.2M | $98.3M | -$601.1M | -$205.0M | -$178.5M |
| Net income | -$724.2M | -$1.6M | -$599.5M | -$205.3M | -$176.1M |
| Diluted EPS | -$5.11 | -$0.01 | -$5.00 | -$1.92 | -$1.67 |
| Operating cash flow | -$271.9M | $179.6M | -$462.9M | -$153.9M | -$136.1M |
| Total assets | $1.74B | $1.39B | $1.14B | $765.6M | $691.9M |
| Shareholders' equity | $50.3M | $466.1M | $185.4M | $271.3M | $398.5M |
As ARROWHEAD PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Nov 12, 2026 ↗
Stock Splits
- 1-for-10Reverse splitNov 17, 2011
- 1-for-65Reverse splitJan 15, 2004
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03Material agreement · Direct financial obligationNov 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About ARROWHEAD PHARMACEUTICALS, INC.
A.Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are approximately 20 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3), including both partnered and wholly-owned candidates. In addition, the Company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company achieved a transformational milestone with its fi…

